Oncolytics Biotech, Inc. (USA)

Oncolytics Biotech® Inc. Closes Bought Deal Financing for Total Gross Proceeds of Cdn$21.3 Million

8 Stocks Under $10 Moving Higher

Oncolytics Biotech rises 28.5%

Oncolytics Biotech rises 26.8%

Oncolytics Biotech Inc. Announces C$15 Million Bought Deal Financing

Oncolytics Biotech (ONCY) Announcs Offering of 3.57M Shares for Cdn$4.20/Share

Oncolytics Biotech Inc. Announces Phase 2 Clinical Trial of REOLYSIN in Combination with Gemcitabine in Pancreatic Cancer Reaches Primary Endpoint

Oncolytics Biotech: Phase 2 clinical trial of REOLYSIN with Gemcitabine

Oncolytics Biotech® Inc. Announces Phase 2 Clinical Trial of REOLYSIN® in Combination with Gemcitabine in Pancreatic Cancer Reaches Primary Endpoint

Oncolytics Biotech Inc. Announces Start of Conformity Testing with SAFC

Oncolytics Biotech announces start of conformity testing with SAFC

Oncolytics Biotech® Inc. Announces Start of Conformity Testing with SAFC®

Oncolytics Biotech Inc. Announces Positive Results of U.S. Phase 2 Clinical Trial Investigating REOLYSIN in Combination with Paclitaxel and Carboplatin in Head and Neck Cancers

Oncolytics: positive results of U.S. Phase 2 REOLYSIN trial with Paclitaxel

Oncolytics Biotech® Inc. Announces Positive Results of U.S. Phase 2 Clinical Trial Investigating REOLYSIN® in Combination with Paclitaxel and Carboplatin in Head and Neck Cancers

Oncolytics Biotech Inc. to Host Conference Call to Discuss Clinical Data Being Presented at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference

Oncolytics Biotech® Inc. to Host Conference Call to Discuss Clinical Data Being Presented at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference

Oncolytics Biotech® Inc. Announces Third Quarter 2011 Results

Oncolytics Biotech Announces Appointments to Senior Management Team

Oncolytics Biotech reports Q3 EPS (9c) vs. consensus (11c)

Oncolytics Biotech® Inc. Announces Third Quarter 2011 Results

Oncolytics Biotech Announces Appointments to Senior Management Team

Wall Street's Buy List

Media Advisory - Oncolytics Biotech® Inc. to Present at the JMP Securities Healthcare Conference

Media Advisory - Oncolytics Biotech® Inc. to Present at the JMP Securities Healthcare Conference

Oncolytics Biotech management to meet with RBC Capital

Media Advisory - Oncolytics Biotech® Inc. to Present at the Wedbush 2011 Life Sciences Management Access Conference

Oncolytics Biotech® Inc. to Present at 31st Canaccord Genuity Growth Conference

Oncolytics Biotech Inc. Announces Publication of Preclinical Research on Synergistic Combination of Chemotherapy with Oncolytic Virotherapy

Oncolytics Biotech announces report on REOLYSIN

Oncolytics Biotech® Inc. Announces Publication of Preclinical Research on Synergistic Combination of Chemotherapy with Oncolytic Virotherapy

Oncolytics Biotech reports Q2 EPS (10c) vs. consensus (9c)

Oncolytics Biotech® Inc. Announces Second Quarter 2011 Results

One Biotech Stock to Avoid

Oncolytics Biotech® Inc. Collaborators Present Positive REOLYSIN® Clinical Trial Results At The 14th World Conference On Lung Cancer

Oncolytics Biotech Inc. Collaborators Present Positive REOLYSIN Clinical Trial Results at the 14th World Conference on Lung Cancer

Oncolytics Biotech Collaborators Present Positive REOLYSIN Clinical Trial Results at the 14th World Conference on Lung Cancer

Oncolytics Biotech® Inc. Collaborators Present Positive REOLYSIN® Clinical Trial Results at the 14th World Conference on Lung Cancer

Oncolytics Biotech names Gill as chief medical officer

Oncolytics Biotech Announces Appointment of Dr. George M. Gill as Chief Medical Officer